文献速递角膜与眼表疾病

口服伏立康唑在真菌性角膜溃疡穿透性角膜移植中的治疗作用:MUTT II 随机试验的病例对照分析

Therapeutic Penetrating Keratoplasty Button Cultures in The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole Versus Placebo.
PubMed 文献 · Am J Ophthalmol · 2018-06-06

该研究为多中心双盲随机安慰剂对照试验的非预设二次病例对照分析,比较口服伏立康唑与安慰剂联合局部抗真菌药治疗丝状真菌性角膜炎。结果显示口服伏立康唑组穿透性角膜移植(TPK)植片培养阳性率无显著差异(P=.74),因药物治疗无反应而手术者培养阳性风险显著高于因穿孔手术者(OR 10.64,P=.003),提示感染而非炎症是病情恶化原因。

要点

  • 口服伏立康唑组TPK植片培养阳性率与安慰剂组无显著差异(OR 1.26,95%CI 0.32-4.87,P=.74)。
  • 因药物治疗无反应行TPK者培养阳性风险显著高于因穿孔手术者(OR 10.64,95%CI 2.16-51.70,P=.003)。
  • TPK每延迟1天,真菌培养阳性几率降低0.94倍(95%CI 0.90-0.98,P=.005)。

核心结论

  • 在局部抗真菌治疗基础上加用口服伏立康唑对严重丝状真菌性角膜溃疡似无获益。
  • 许多患者病情恶化的原因似乎是感染而非炎症。

研究设计与样本

  • 非预设的二次病例对照分析,源自多中心、双盲、随机安慰剂对照临床试验。
  • 研究对象为涂片阳性丝状真菌性溃疡且视力20/400或更差、最终行治疗性穿透性角膜移植(TPK)的患者,随机接受口服伏立康唑或口服安慰剂,所有患者均接受局部抗真菌滴眼液。

主要发现

  • 194例入组患者中95例(49.5%)行TPK,平均20.9天(标准差15.2天,范围2-71天)。
  • 95例TPK中67例(71%)有植片培养结果,其中45例(67%)丝状真菌培养阳性。
  • TPK时间每增加1天,真菌培养阳性几率降低0.94倍(95%CI 0.90-0.98,P=.005)。
  • 控制TPK时间和基线病原体后,口服伏立康唑组TPK植片培养阳性几率增加1.26倍,但无统计学显著性(95%CI 0.32-4.87,P=.74)。
  • 因药物治疗无反应行TPK者培养阳性可能性是因穿孔手术者的10.64倍,具统计学显著性(95%CI 2.16-51.70,P=.003)。

临床怎么用

  • 对于严重丝状真菌性角膜溃疡,在局部抗真菌治疗基础上加用口服伏立康唑似无额外获益。
  • 因药物治疗无反应而行TPK的患者,植片培养阳性的可能性较高。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare oral voriconazole vs placebo in addition to topical antifungals in the treatment of filamentous fungal keratitis. DESIGN: Non-prespecified, secondary case-control analysis from a multicenter, double-masked, randomized placebo-controlled clinical trial. METHODS: Study Participants: Patients with smear-positive filamentous fungal ulcers and visual acuity of 20/400 or worse who eventuated to therapeutic penetrating keratoplasty (TPK). INTERVENTION: Study participants were randomized to oral voriconazole vs oral placebo; all received topical antifungal drops. MAIN OUTCOME MEASURES: TPK button culture positivity. RESULTS: A total of 95 of 194 (49.5%) study participants enrolled at Madurai, Coimbatore, or Pondicherry, India eventuated to TPK in an average of 20.9 days (standard deviation 15.2 days, range 2-71 days). TPK button cultures were available for 67 of 95 (71%) of the TPKs performed and were positive for filamentous fungus in 45 of 67 (67%) cases. For each 1-day increase in the time to TPK there was 0.94-fold decreased odds of fungal culture positivity (95% confidence interval [CI] 0.90-0.98, P = .005). Those randomized to oral voriconazole had 1.26-fold increased odds of TPK button culture positivity after controlling for time to TPK and baseline organism, but this was not statistically significant (95% CI 0.32-4.87; P = .74). Those who underwent TPK for lack of response to medical therapy were 10.64-fold more likely to be culture positive than if the indication for surgery was perforation and this was statistically significant (95% CI 2.16-51.70; P = .003). CONCLUSIONS: There appears to be no benefit to adding oral voriconazole to topical antifungal agents in the treatment of severe filamentous fungal ulcers. Infection rather than inflammation appears to be the reason for the worsening clinical picture in many of these patients.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Cho J, Prajna NV, Lalitha P, et al. Therapeutic Penetrating Keratoplasty Button Cultures in The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole Versus Placebo. Am J Ophthalmol. 2018. PMID: 29758184. doi:10.1016/j.ajo.2018.05.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。